Increased serum thymidine kinase following chemotherapy
Aysegul Akbayl, Selda Dernirtas-and Yasemin Yavuz' From the I Department 01" Biochemistry, Faculty 01" Medicine, Ankara University, the 2Central Laboratory, ibn-i Sina Hospital, and the 3Department of Biostatistics, Faculty 01" Medicine, Ankara University, DekanlJk-06100, Sthhiye-Ankara, Turkey Thymidine kinase (TK, EC 2.7.1.21) is considered a salvage enzyme of DNA synthesis and is associated with the G liS phase of dividing cells.' Serum TK concentration is considered to be a guide to the proliferative state, and increases in TK activity appear to correlate with progression of human neoplasia.I?
Tumour lysis syndrome (TLS), a potentially fatal complication of anti-cancer therapy, is usually seen in haematological malignancies, but has also been observed in patients with a variety of solid tumours.:' In this pilot study we measured thymidine kinase after chemotherapy to examine whether it is valuable to monitor response to therapy and predict complications like TLS.
MATERIALS AND METHODS
Serum TK activity was measured in 26 patients receiving chemotherapy (nine patients with breast cancer, four with Hodgkin's disease, nine with colorectal and four with stomach adenocarcinomas). The diagnosis and staging of tumours were confirmed pathologically. The patients' mean age was 44 (range 27-58) years. All patients were selected randomly from firsttime chemotherapy receivers without considering the pathological grade or stage of the malignancy.
Patients with breast cancer received the regimen cyclophospharnide/adriamycin or cisplatin/ taxol; patients with Hodgkin's disease received 5-fluorouracil/folinic acid or cisplatinj5-fluorouracil or cisplatinjdecarbazine; patients with colorectal tumours received I-phosphamidej cisplatinjetoposidejprednisolone; and those with stomach adenocarcinomas received cisplatinj5fluorouracil or cisplatin/cytosine arabinoside regimens, with doses adjusted for the particular patient.
The study was conducted in accordance with the Helsinki Declaration of 1975/1983. Correspondence: Aysegul Akbay. E-mail: akbayrs.dialup.ankara.edu.tu Serum samples were drawn immediately before and 4 h after the administration of chemotherapy and stored for less than 1 week at -80°e. Samples were assayed in a single run using the radiolabelled assay Proliflgen'P TK-REA (AB Sangtec Medical, Bromma, Sweden) in accordance with the manufacturer's instructions. TK is stable for at least 6 months at -80 Ge. The interassay coefficients of variation were 5·7% and 3·2% at 4·9 UjL and 34·8 UjL, respectively.
Pre-and post-chemotherapy lactate dehydrogenase (LDH) determinations were analysed on the Synchron CX7 (Beckman, Fullerton CA, USA) using the LDH procedure provided by Biocon (Rockville MD, USA).
The variance between groups was tested by the Kruskal-Wallis and Dunn tests. The difference in subgroups were evaluated by the Wilcoxon matched test. The relationship between post-chemotherapy LDH and TK and pre-and post-chemotherapy TK was evaluated by Spearman correlation coefficients.
RESULTS AND DISCUSSION
The results are shown in Table I . Postchemotherapy TK values were significantly higher than the pre-chemotherapy values in the mammary cancer group and slightly different in other groups. TK values after chemotherapy were significantly different between the four groups (P=O'OI46) but not before chemotherapy (P=O'2113), suggesting that TK may be an indicator of the response of different tumours to different therapy. There were significant differences between mammary cancer and Hodgkin's groups and Hodgkin's and colorectal cancer groups.
TK has been investigated as an aid to the diagnosis and management of tumours; however, to our knowledge, this is the first study reporting an increase in TK activity in response to chemotherapy, suggesting the extent of cell Results are mean±SD. Numbers in brackets indicate the number of patients. In a study of 160 blood donors, >95% had a serum TK value of less than 6·1 U/L. Reference interval for LDH assay for adults is 101-233 U/L. breast cancer which contained high levels of TK had increased risks of relapse and death. Moreover, high TK values were more often found in larger tumours. This may indicate that TK may be of value in predicting response to therapy. It is notable that TKI, which is involved in cell proliferation from G I to S, is not detectable in resting cells but may originate from rapidly proliferating non-tumour sources. Clinically, TLS is seen within 48 h after starting chemotherapy." In our study, we selected a single-time point: 4 h. Even though none of the patients developed TLS, the results suggest that TK may be a marker for monitoring cell death.
LDH is perhaps the most common clinical enzyme used in cancer patients for prognostic purposes. 70% of patients with liver metastases and 2Q-60% of patients who do not have hepatic metastases have elevated total LDH activity.
Especially high values are associated with Hodgkin's disease and abdominal malignancies. Even though serum levels of LDH have been assayed to monitor changes in tumour burden after chemotherapy, elevations of LDH in patients with cancer are suggested to be too erratic to be of use in clinical diagnosis.' The results of this experiment did not reveal significant difference between pre-chemotherapy LDH and post-chemotherapy LDH values, suggesting that LDH is not useful in monitoring response to treatment. In a retrospective study of 25 patients with solid tumour who developed TLS associated with a variety of treatment regimens, increased serum LDH was reported in 75% of patients, while two patients with initially elevated serum LDH levels exhibited a rapid decrease in levels after treatment."
In this study, breast cancer patients showed a significant difference between TK activities before and after treatment. Spearman correlation coefficients between pre-treatment and post-treatment TK activities were r = 0·83 (P=0'005) for breast cancer, r=0'9 (P=O'OOI) for colorectal adenocarcinomas and r = 1·0 (P<O·OOI) for stomach adenocarcinomas. The significant correlation between the pre-and post-chemotherapy TK values may be related to tumour activity before chemotherapy and the relationship of tumour lysis to tumour activity or size following therapy.
We conclude that increased serum TK values may be a potential indicator of cell death as early as 4 h following chemotherapy.
